Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways

Molecular Oncology

Volumn 10, Issue 1, 2016, Pages 113-125

  Tong, Xiaoguang ^a,b   Barbour, Mark ^b   Hou, Kezuo ^a   Gao, Chao ^a   Cao, Shuang ^a   Zheng, Jingli ^a   Zhao, Yang ^a   Mu, Rong ^c   Jiang, Hui Rong ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Fl hIL 33; Invasion; Metastasis; Ovarian cancer; Survival

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; INTERLEUKIN 33; KI 67 ANTIGEN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; PROTEIN KINASE INHIBITOR;

ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME; UPREGULATION; FEMALE; GENE SILENCING; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TUMOR INVASION;

CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING;

EID: 84953356581     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.06.004     Document Type: Article

References (43)

1. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002, 7(Suppl 5):20-28.
2. Baekkevold E.S., Roussigne M., Yamanaka T., Johansen F.E., Jahnsen F.L., Amalric F., Brandtzaeg P., Erard M., Haraldsen G., Girard J.P. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 2003, 163:69-79.
3. Barbour M., Allan D., Xu H., Pei C., Chen M., Niedbala W., Fukada S.Y., Besnard A.G., Alves-Filho J.C., Tong X., Forrester J.V., Liew F.Y., Jiang H.R. IL-33 attenuates the development of experimental autoimmune uveitis. Eur. J. Immunol. 2014, 44:3320-3329.
4. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 2005, 18(Suppl 2):S19-S32.
5. Bergis D., Kassis V., Ranglack A., Koeberle V., Piiper A., Kronenberger B., Zeuzem S., Waidmann O., Radeke H.H. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl. Oncol. 2013, 6:311-318.
6. Besnard A.G., Togbe D., Guillou N., Erard F., Quesniaux V., Ryffel B. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur. J. Immunol. 2011, 41:1675-1686.
7. Chen S.F., Nieh S., Jao S.W., Wu M.Z., Liu C.L., Chang Y.C., Lin Y.S. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J. Pathol. 2013, 231:180-189.
8. Choi Y.S., Choi H.J., Min J.K., Pyun B.J., Maeng Y.S., Park H., Kim J., Kim Y.M., Kwon Y.G. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009, 114:3117-3126.
9. Fang K.M., Yang C.S., Lin T.C., Chan T.C., Tzeng S.F. Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells. Neuro. Oncol. 2014, 16:552-566.
10. Gao K., Li X., Zhang L., Bai L., Dong W., Shi G., Xia X., Wu L. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 2013, 335:463-471.
11. Gao X., Wang X., Yang Q., Zhao X., Wen W., Li G., Lu J., Qin W., Qi Y., Xie F., Jiang J., Wu C., Zhang X., Chen X., Turnquist H., Zhu Y., Lu B. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J. Immunol. 2015, 194:438-445.
12. Goff B.A., Mandel L., Muntz H.G., Melancon C.H. Ovarian carcinoma diagnosis. Cancer 2000, 89:2068-2075.
13. Gonzalez-Campora R., Delgado M.D., Amate A.H., Gallardo S.P., Leon M.S., Beltran A.L. Old and new immunohistochemical markers for the diagnosis of gastrointestinal stromal tumors. Anal. Quant. Cytol. Histol. 2011, 33:1-11.
14. Heintz A.P., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., Ngan H.Y., Pecorelli S., Beller U. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006, 95(Suppl 1):S161-S192.
15. Hu L.A., Fu Y., Zhang D.N., Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac. J. Cancer Prev. 2013, 14:2563-2566.
16. Hu W.T., Li M.Q., Liu W., Jin L.P., Li D.J., Zhu X.Y. IL-33 enhances proliferation and invasiveness of decidual stromal cells by up-regulation of CCL2/CCR2 via NF-kappaB and ERK1/2 signaling. Mol. Hum. Reprod. 2014, 20:358-372.
17. Ishikawa K., Yagi-Nakanishi S., Nakanishi Y., Kondo S., Tsuji A., Endo K., Wakisaka N., Murono S., Yoshizaki T. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Auris Nasus Larynx 2014, 41:552-557.
18. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59:225-249.
19. Jiang H.R., Milovanovic M., Allan D., Niedbala W., Besnard A.G., Fukada S.Y., Alves-Filho J.C., Togbe D., Goodyear C.S., Linington C., Xu D., Lukic M.L., Liew F.Y. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur. J. Immunol. 2012, 42:1804-1814.
20. Jovanovic I., Radosavljevic G., Mitrovic M., Juranic V.L., McKenzie A.N., Arsenijevic N., Jonjic S., Lukic M.L., et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur. J. Immunol. 2011, 41:1902-1912.
21. Jovanovic I.P., Pejnovic N.N., Radosavljevic G.D., Pantic J.M., Milovanovic M.Z., Arsenijevic N.N., Lukic M.L. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 2014, 134:1669-1682.
22. Kurian A.W., Balise R.R., McGuire V., Whittemore A.S. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecol. Oncol. 2005, 96:520-530.
23. Kurowska-Stolarska M., Stolarski B., Kewin P., Murphy G., Corrigan C.J., Ying S., Pitman N., Mirchandani A., Rana B., van Rooijen N., Shepherd M., McSharry C., McInnes I.B., Xu D., Liew F.Y. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 2009, 183:6469-6477.
24. Lavoue V., Thedrez A., Leveque J., Foucher F., Henno S., Jauffret V., Belaud-Rotureau M.A., Catros V., Cabillic F. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J. Transl. Med. 2013, 11:147.
25. Liew F.Y. IL-33: a Janus cytokine. Ann. Rheum. Dis. 2012, 71(Suppl 2):i101-i104.
26. Liu J., Shen J.X., Hu J.L., Huang W.H., Zhang G.J. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front. Immunol. 2014, 5:141.
27. Lohning M., Stroehmann A., Coyle A.J., Grogan J.L., Lin S., Gutierrez-Ramos J.C., Levinson D., Radbruch A., Kamradt T. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. U S A 1998, 95:6930-6935.
28. Lu D.P., Zhou X.Y., Yao L.T., Liu C.G., Ma W., Jin F., Wu Y.F. Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer 2014, 14:198.
29. Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R., Frumovitz M., Atkinson E.N., Smith D.I., Hartmann L., Fishman D., Berchuck A., Whitaker R., Gershenson D.M., Mills G.B., Bast R.C., Lu K.H. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 2005, 11:6116-6126.
30. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334:1-6.
31. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., Baker A.H., McInnes I.B., Liew F.Y. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 2008, 205:339-346.
32. Milovanovic M., Volarevic V., Radosavljevic G., Jovanovic I., Pejnovic N., Arsenijevic N., Lukic M.L. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 2012, 52:89-99.
33. Moritz D.R., Rodewald H.R., Gheyselinck J., Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J. Immunol. 1998, 161:4866-4874.
34. Oshikawa K., Yanagisawa K., Tominaga S., Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin. Exp. Allergy 2002, 32:1520-1526.
35. Pei C., Barbour M., Fairlie-Clarke K.L., Allan D., Mu R., Jiang H.R. Emerging role of interleukin-33 in autoimmune diseases. Immunology 2014, 141:9-17.
36. Schmieder A., Multhoff G., Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 2012, 60:514-521.
37. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., Kastelein R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
38. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009, 86:1065-1073.
39. Stirling D., Evans D.G., Pichert G., Shenton A., Kirk E.N., Rimmer S., Steel C.M., Lawson S., Busby-Earle R.M., Walker J., Lalloo F.I., Eccles D.M., Lucassen A.M., Porteous M.E. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system. J. Clin. Oncol. 2005, 23:5588-5596.
40. Sun P., Ben Q., Tu S., Dong W., Qi X., Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig. Dis. Sci. 2011, 56:3596-3601.
41. Xu D., Chan W.L., Leung B.P., Huang F., Wheeler R., Piedrafita D., Robinson J.H., Liew F.Y. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 1998, 187:787-794.
42. Zeyda M., Wernly B., Demyanets S., Kaun C., Hammerle M., Hantusch B., Schranz M., Neuhofer A., Itariu B.K., Keck M., Prager G., Wojta J., Stulnig T.M. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int. J. Obes. 2013, 37:658-665.
43. Zhou J., Song J., Ping F., Shang J. Enhancement of the p38 MAPK and PKA signaling pathways is associated with the pro-melanogenic activity of interleukin 33 in primary melanocytes. J. Dermatol. Sci. 2014, 73:110-116.